![Thomas Huenig](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Thomas Huenig
Direttore/Membro del Consiglio presso TeGenero AG
Posizioni attive di Thomas Huenig
Società | Posizione | Inizio | Fine |
---|---|---|---|
TeGenero AG
![]() TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Direttore/Membro del Consiglio | 01/06/2000 | - |
Storia della carriera di Thomas Huenig
Formazione di Thomas Huenig
Wuerzburg Schweinfurt University of Applied Sciences | Doctorate Degree |
Statistiche
Distribuzione geografica
Germania | 3 |
Posizioni
Director/Board Member | 1 |
Doctorate Degree | 1 |
Settori
Health Technology | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
TeGenero AG
![]() TeGenero AG Pharmaceuticals: MajorHealth Technology TeGenero AG discovers and develops novel therapeutics. It is a biopharmaceutical company providing services in the identification and development of effective and applicable therapeutics for the treatment of severe immunological disorders. It's first development candidate TGN1412, a SuperMAB with specificity for the T cell surface receptor CD28 is in non-clinical development. Clinical applications of SuperMAB and its derived compounds are expected to solve unmet medical needs in the fields of cancer-related immunodeficiencies such as B-cell chronic lymphocytic leukaemia and autoimmune/inflammatory diseases like rheumatoid arthritis. The company was founded in 2000 and is headquartered in Wurzburg, Germany. | Health Technology |
- Borsa valori
- Insiders
- Thomas Huenig
- Esperienza